Cargando…
SUN-255 PATRO Children, a Multi-Center, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment: Comparing United States (US) and Rest of World (ROW) Data
Introduction: PATRO Children is a non-interventional, international, longitudinal study of the long-term safety of a recombinant human growth hormone (rhGH; Omnitrope®, Sandoz) in patients requiring this therapy. Here we compare data from participants in the US with the ROW. Methods: The study popul...
Autores principales: | Backeljauw, Philippe, Kanumakala, Shankar, Lechuga, Alfonso, Loche, Sandro, Schwab, Karl-Otfried, Miller, Brad, Levy, Richard, McCormick, Kenneth, Zouater, Hichem, Zabransky, Markus, Campbell, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553049/ http://dx.doi.org/10.1210/js.2019-SUN-255 |
Ejemplares similares
-
Safety and effectiveness of Omnitrope(®) (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data
por: Backeljauw, Philippe, et al.
Publicado: (2022) -
SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019) -
Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020) -
SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)
por: Schwarz, Hans-Peter, et al.
Publicado: (2019) -
Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020)